Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 11/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769941 | 0.93 | PRKCQ (0.41) | PRKCQSYK | |
| SCHEMBL15769771 | 0.85 | PRKCQ (0.45) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL15769286 | 0.85 | PRKCQ (0.42) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL20752084 | 0.79 | EGFR (0.47) | EGFRSYKBCL6 | |
| SCHEMBL15769283 | 0.79 | SYK (0.58) | EGFRPRKCQCCNT1CCNE1CDK2 | |
| SCHEMBL15769896 | 0.78 | CDK1 (0.41) | EGFRPRKCQ | |
| SCHEMBL15770096 | 0.78 | STK17A (0.41) | PRKCQ | |
| SCHEMBL20752060 | 0.78 | STK17A (0.41) | PRKCQ | |
| SCHEMBL15769547 | 0.78 | PRKCQ (0.45) | PRKCQSYK | |
| SCHEMBL15769152 | 0.78 | PKMYT1 (0.42) | EGFRPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | claimed |
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
| WO-2014089112-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | EGFR 2549/4885PRKCQ 5/4885CCNT1 3618/4885 |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | EGFR 2549/4885PRKCQ 5/4885CCNT1 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.